Related Experiment Video
Updated: Apr 24, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Lipid Profile Differences in HIV-Infected Populations With Metabolic Dysfunction-Associated Steatotic Liver Disease:
Yovita Hartantri1, Sherly Lawrensia2, Steven Yulius Usman3
1Division of Tropical and Infectious Diseases, Department of Internal Medicine, Hasan Sadikin General Hospital, Faculty of Medicine Universitas Padjadjaran West Java Indonesia.
Introduction:
Advances in HIV management have transformed HIV into a chronic condition, resulting in improved prognosis and increased survival among people living with HIV (PLWH). Traditional risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD)-including dyslipidemia-are prevalent in PLWH. This systematic review and meta-analysis aim to synthesize current evidence on lipid profile disturbances as contributors to MASLD in PLWH.
Methods:
This systematic review and meta-analysis were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered in PROSPERO with registration number CRD420251054477. We searched seven databases to identify studies reporting the prevalence and characteristics of MASLD in PLWH. Meta-analysis was conducted using Review Manager 5.4.1. Mean differences (MDs) were calculated using a random-effects model. Risk of bias was assessed using the ROBINS-E tool.
Results:
A total of 17 studies comprising 3933 HIV-positive participants were included, among whom 1226 (37%) had MASLD. Male sex was significantly associated with MASLD (OR = 1.57; 95% CI: 1.13-2.17; p = 0.007). MASLD was significantly associated with higher body mass index (BMI) (MD = 3.23 kg/m²; p < 0.00001). Lipid profile analysis revealed that MASLD patients had higher total cholesterol (MD = 6.62 mg/dL; p = 0.01), low density lipoprotein (LDL) (MD = 3.83 mg/dL; p = 0.01), triglycerides (MD = 63.02 mg/dL; p < 0.00001), and lower high density lipoprotein (HDL) (MD = -3.73 mg/dL; p < 0.0001).
Conclusion:
This study demonstrates a significant difference in lipid profiles (higher total cholesterol, LDL, triglycerides, and lower HDL) among PLWH who develop MASLD, suggesting a potential metabolic signature associated with this comorbidity.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

